By Ryan Davis ( November 28, 2018, 5:50 PM EST) -- Generics makers Roxane and Teva urged the full Federal Circuit Tuesday not to rehear a decision invalidating four Acorda patents on the multiple sclerosis drug Ampyra, arguing that the ruling was a careful application of the so-called blocking patent doctrine, not an expansion of it....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.